Investor Overview

Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate underexplored protein targets and the function of RNA to treat multiple incurable diseases.

Molecure is developing a diverse portfolio spanning five distinct research programs with the support of leading academic research institutions around the world, including Yale University, Rutgers University, the Flemish Institute of Biotechnology (VIB) in Ghent, the University of Michigan, and the International Institute of Molecular and Cell Biology in Warsaw (MIBMiK) which has expertise in studying the structure and function of RNA.

Our most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis. Molecure started a Phase II trial in patients with sarcoidosis in March 2024.

Molecure also sees tremendous potential for OATD-01, based on the results of preclinical studies and scientific publications to date, in the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and is currently focusing Business Development efforts in this area.

Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is at the stage of Phase I clinical development.